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Introduction
Gamma-amino-butyric acid (GABA) is a major neurotransmitter in the central nervous system (CNS) of adult mammals, but also a messenger molecule in many nonneuronal tissues. The GABA effects are mediated via ionotropic GA-BA A receptors and metabotropic GAB-A B receptors. GABA A receptors are GA-BA activated chloride channels that consist of five subunits (see . Fig. 1 ) and are targets of many clinically relevant medications [1] . Barbiturates, neuro-active steroids, several general anesthetics, and benzodiazepines are among the classes of drugs acting via GABA A receptors (see . Excursion 1). The existence of multiple ligand binding sites at the receptors as well as of multiple GABA A receptor subtypes, results in a highly complex pharmacology.
GABA A receptors are the most widespread inhibitory receptors in the CNS. At higher intracellular chloride concentrations, however, these receptors can also have excitatory effects mediated by chloride outflux from the cells. A total of 19 genes encode for GABA A receptor subunits (alpha1-6, beta1-3, gamma1-3, delta, epsilon, theta, pi, rho1-3). The receptors themselves comprise five subunits and belong to the family of the pentameric ligand-gated ion channels (cys-loop receptors), together with the nicotinic acetylcholine receptors (nAChRs), the serotonin type 3 (5-HT 3 ) receptors, the glycine receptors, the acetlycholine-binding protein (AChBP), the bacterial proteins Gloeobacter violaceus ligand-gated ion channel and Erwinia chrysantemi ligand-gated ion channel, as well as the glutamate-activated chloride channel (GluCl) of Caenorhabditis elegans [1] . All cys-loop receptor subunits possess a common domain organization with an N-terminal domain that contains the cys-loop and ligand binding sites for the agonist or allosteric modulators, a transmembrane (TM) domain composed of four helical segments, and an intracellular domain that is interspaced between TM3 and TM4, see . Fig. 1 . The transmitter binding sites of this family are at extracellular interfaces between two subunits, whereby one is known as "principal subunit" and the other as "complementary subunit". The principal subunit, per convention, contributes the "plus" side to the interface and the complementary subunit the "minus" side, see . Fig. 1 . Each subunit contributes several discontinuous segments to the interface -those involved in ligand recognition are traditionally termed "loops A thru G", see . Fig. 1 . In the transmembrane domain the terms "plus side", which is formed by parts of TM2 and TM3 of the principal subunit; and "minus side", formed by parts of TM2 and TM1 of the complementary subunit, are also commonly used, see . Fig. 1 .
In the most common GABA A receptors with the arrangement shown in . Fig. 1 , the GABA binding site is located at the extracellular interface which is formed by the principal (plus) side of the beta subunit and the complementary (minus) side of the alpha subunit. Thus these receptors feature two GABA binding sites. The benzodiazepine binding site is at the homologous interface between the alpha subunits' plus, and the gamma subunits' minus side. The binding site recently identified by our group at the alpha + beta − interface can be used by pyrazoloquinolinones [1] . For the gamma + beta − interface no ligands have been described so far. The binding of GABA to its two sites leads to a change in conformation that can open the chloride channel of the receptor. Binding of benzodiazepines to their site, or of pyrazoloquinolinones to the site at the alpha + beta − interface, does not lead to opening of the channel, but the conformational changes induced by these agents leads to a modulation of the GABA effect at the receptor.
These two binding sites are thus fundamentally different from those for barbiturates, steroids, or other sedative anesthetics, which are located in the TM domain of the receptors. Low concentrations of these agents lead to an allosteric enhancement of the GABA effect, and high concentrations open the channel directly in the absence of GABA. Due to this GA-BA-mimetic effect, barbiturates, steroids, or anesthetics are thus much more toxic in overdose than the benzodiazepines.
Depending on the structure of ligands, binding events at individual sites can lead to conformational changes of the receptor that enhance (positive allosteric modulation) or reduce (negative allosteric modulation) the GABA effect. Ligands that induce no or insufficient conformational changes are called null modulators (or silent modulators). They exert no effect on the receptor activity, but can effectively displace positive or negative modulators and thus, inhibit their actions -as flumazenil does when it is used as antagonist of benzodiazepine overdose. Such bidirectional effects of ligand families do not only occur among the benzodiazepines, where positive, negative, and silent modulators are known, but also presumably among ligands of other binding sites on the receptor. Clear proof of this hypothesis is still lacking, however, because for many binding sites null-modulators have not yet been identified.
Subtype selective ligands as therapeutic prospects of the future
Currently available drugs acting on GAB-A A receptors all interact with multiple receptor subtypes -they thus must be classified as unselective, or partially selective for certain receptor pools. Benzodiazepines for example act on receptors that contain an alpha1, alpha2, alpha3, or alpha5 subunit together with a neighboring gamma2 subunit, see . Fig. 1 . Today it is clear from partially selective compounds and genetically manipulated animals that receptors containing any one of these four alpha subunits influence distinct brain functions in vivo. The sedating and hypnotic effects are mainly mediated by alpha1-receptors, while anxiolytic and antihyperalgesic effects can be elicited via alpha2 containing receptors [2] . Nonsedating anxiolytics or GABAergic antihyperalgetics that may relieve pathological pain should thus be primarily and strongly acting at alpha2 receptors, while having ideally no, or only weak effects on alpha1 receptors. Alpha5 subunit containing receptors allow the bidirectional modulation of cognitive (memory related) processes. A negative allosteric modulator selective for these receptors is currently investigated in a clinical trial in Down syndrome patients [2] .
The comparatively small population of delta containing receptors is also turning out to form an interesting receptor pool that due to its high steroid sensitivity controls many hormonally influenced functions in the limbic system and the cortex. Compounds with selectivity for one or the other subtype within this receptor pool should thus have much more specific effects than the so far used GABA A receptor medications. Possible implications of delta containing receptors in pathological mechanisms and as therapeutic targets are under intense investigation [3] .
Recent developments focus also on GABA A receptors on non-neuronal cell types. Outside the CNS, GABA A receptors are found in the autonomic nervous system and in endocrine and reproductive organs [4] , in the beta-cells of the pan-
Excursion 1 Clinical pharmacology of GABA A receptors
Drugs that act on GABA A receptors were in clinical use long before the receptors were identified. The first barbiturate based drug, 5,5-diethyl barbituricacic, was marketed by Merck as sleeping aid in 1903 already under the trade name Veronal. Barbiturates have dose dependently sedative, then hypnotic and at high doses narcotic effects. In addition, they are anticonvulsants. At low concentrations they enhance the effects of GABA on the GABA A receptors. At higher concentrations they can activate the receptors directly. At even higher concentrations barbiturates also act at glutamatergic AMPA receptors and voltage-sensitive sodium channels. Due to their high toxicity at overdose, barbiturates legally are allowed to be used in Germany and in Switzerland only for certain clinical applications since 1992. Due to the broad abundance of anxiety disorders, compounds able to fight anxiety were identified early. Presumably, one of the first drugs to relieve anxiety was ethanol, that is even used today to enhance courage and to fight social anxiety by consuming an initial drink at invitations and receptions. Ethanol at low doses enhances the action of GABA at GABA A receptors and by that, reduces anxiety. Ethanol might modulate individual GABA A receptor subtypes with differential potency and seems to act at GABA A receptors via several binding sites at different locations. The actual locations of these sites have not been unequivocally unraveled. At higher concentrations, all GABA A receptors will become involved in ethanol action, but also other transmitter systems will be modulated by ethanol, leading to sedation, hypnotic actions, and anesthesia. At even higher concentrations, ethanol interacts with many proteins and transmitter systems and develops a cell toxicity independent from the GABA system. In addition to ethanol and barbiturates, methaqualone, meprobamate, and anesthetics, such as chloralhydrate, were used as anxiolytics. All these drugs seem to act via GABA A receptors, but due to their strong sedative action they were not suitable for treating anxiety disorders. The serendipitous identification of the anxiolytic action of the benzodiazepine chlordiazepoxide by the pharmaceutical company Hoffmann La Roche then led to a much more specific treatment of these disorders and since 1960, to a rapid clinical introduction of Librium, Valium, and other benzodiazepines. Benzodiazepines, due to their anxiolytic, anticonvulsive, muscle-relaxant, and sedative-hypnotic actions, became soon the most heavily prescribed drugs in clinical use at that time. But only 15 years after their introduction in clinical use evidence accumulated that these compounds might act via the benzodiazepine site of GABA A receptors, that are located at the extracellular interface between an alpha and a gamma subunit of these receptors (alpha + gamma −, see . In the meantime, around hundred different compound classes have been identified that act via the benzodiazepine binding site of GABA A receptors. Several of these compounds are already clinically used. The best known of these compounds is zolpidem, that is marketed in Austria under the commercial name Ivadal as a sleeping pill. While zolpidem exhibits a certain receptor subtype-selectivity, this is not the case with the structually unrelated compounds zopiclone, zaleplon, and divaplon, that also act via the benzodiazepine site of GABA A receptors. In addition, endogenous neurosteroids, such as allopregnanolone, can modulate GABA A receptors with differential potency. This can contribute to the mood-variations during puberty and during the female cycle, as well as during and after pregnancy. The steroids act via several steroid binding sites in the transmembrane region of GABA A receptors. At low concentrations they enhance the action of GABA, at higher concentrations they also can activate GABA A receptors directly. Synthetic steroids are used as anesthetics (alfaxalone) or as antiepileptics (ganaxolone). In addition, some inhalation anesthetics, such as chloroform, isoflurane, halothane, and some intravenous anesthetics, such as etomidate or propofol, are acting via binding sites in the transmembrane region of GABA A receptors.
creas [5] , in certain cells of the immune system [6] , and in epithelial and smooth muscle cells of the respiratory tract [7] . Thus, it was shown recently, that experimental benzodiazepines with alpha5 receptor preferring action relax precontracted airway smooth muscle and influence their intracellular Ca 2+ [7] . Compounds with this profile could thus be developed into asthma medications. GABA A receptors also occur in many tumor types and seem to influence tumor cell growth. From all these studies receptor subtypes emerge that are involved in highly specific functions in neuronal and nonneuronal cells. Selective ligands for these subtypes promise enormous therapeutic potential.
Structure of GABA A receptors and related cys-loop receptors
Many of the pharmacological and global structural properties of GABA A receptor subtypes were well known prior to structural studies providing atomic resolution, such as the localization of the GABA and benzodiazepine binding sites at specific subunit interfaces, see . Fig. 1 . Structural details as well as the localization of many other allosteric binding sites were unclear for a long time though. Therefore, any discovery of subtype-specific ligands was mostly the result of broad drug screens. Sometimes serendipity helped, but such discoveries were only to a small extent hypothesis driven. Since the first crystal structure of a homologous protein was released in 2001 [8] , efforts have focused on homology modeling of binding sites at the atomic level. Such models were also successfully used by our group to investigate the extracellular alpha + beta − interface, as well as for computational docking studies [9] . The first crystal structures were from remote homologues (< 20 % sequence identity), but the development has reached a new milestone with the first crystal structure of a GABA A receptor [10] which raises hopes to soon pursue structure-guided drug design for specific receptor subtypes.
Which binding sites feature subtype-specific structures?. Since so far a crystal structure of only a single GABA A receptor's subtype is available, all statements about structural differences between subtypes thus rest on sequence data and homology models. The so far most investigated binding sites are at the extracellular interfaces between the principal subunit and its loops A, B, and C and the complementary subunit and its loops D, E, F, and G; and at the transmembrane interfaces between the principal segments of TM 2,3 and the complementary segments of TM 1,2 (see . Fig. 1 ). Additional binding sites in the extracellular and transmembrane domains were described in the literature for various compounds, but will not be discussed here.
Regarding the question of subtype specific binding motifs, a sequence comparison among the binding site forming segments of the 19 GABA A receptor subunits reveals that the extracellular loops C and F feature the largest variability. Thus, in principle each extracellular interface between two subunits is unique and can therefore offer a more or less specific pocket for selective ligands if the sequence differences translate into corresponding structural differences. Examples for selective ligands are some experimental benzodiazepines such as the strongly alpha5-preferring compound SH-053-2'F-R-CH3 [2] that is acting at the benzodiazepine binding site, or the exquisitely alpha6/beta2,3 selective "compound 6" that was recently described by us [1] and is acting via the alpha + beta − interface.
The binding pocket that is formed by the transmembrane domain interface displays less variability within subunit classes, but is sufficiently different between classes to be specific for defined receptor pools. For example, the binding site forming sequence on the plus side of theta, epsilon, and pi subunits is distinctly different from all others. Thus, this site also would be suitable for selective targeting by appropriate ligands.
Can the structural variability of binding pockets be predicted using crystal structures?. For all crystal structures, the four letter protein database (PDB, http://www.rcsb.org) identifiers will be indicated below. The only crystal structure of a GABA A receptor available so far, the one of the beta3 homopentamer ([10] 4COF) contains no GABA binding site at the extracellular interface, but one for the synthetic agonist benzamidine and for histamine [1] . Even though no structures of other subtypes are available yet, analysis of crystal structures of homologous proteins allows to estimate the structural variability among subtypes. The same holds true for conformational flexibility.
For a realistic estimate of structural and conformational variability, crystal structures of the glutamate-gated chloride channel (GluCl, particularly 3RIF -one of the avermectin bound structures -and TNV, the apo-GluCl structure), but also 
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GABA A receptor · Subtypes · Structure · Binding sites · Allosteric modulation structures of more remote homologues, specifically of the serotonine type 3 receptor (4PIR), and of a chimera between the alpha7-nAChR and the acetylcholine binding protein (AChBP, 5AFH and 2BYS) are very useful [11] [12] [13] [14] [15] .
The high similarity between the GA-BA A receptor structure (4COF) with the avermectin bound GluCl structure (3RIF) which share 36 % sequence identity, and even with the more remotely homologous 5-HT 3 receptor (4PIR, only 14 % sequence identity) demonstrates impressively that the structural conservation in the cys-loop family is extraordinarily high, see . Fig. 2 . The enormous diversity which furnishes each family member and every receptor subtype with unique pharmacological and electrophysiological properties thus stems from a few highly variable domains, such as the extracellular loops C and F on the one hand, and from subtle differences in structural details on the other hand. Which differences between subtypes must be expected, and how much will subunits from other classes, such as alpha or gamma, differ from the beta3 structure? These questions demand different answers for the different domains and binding sites of the receptor.
Binding sites at extracellular interfaces. Does the structure of the beta3 homo-pentamer enable us to generate accurate models for example of the alpha + gamma − benzodiazepine sites in specific subtypes? Both subunits (plus and minus side) contribute highly conserved segments to this binding site, but also highly variable ones, such as loops C and F -which additionally are flexible as well. Which differences between beta3 and gamma2, or between beta3 and the alpha isoforms must be expected? The sequence identity between beta3 and gamma2 is 34 %, between beta3 and alpha1 it is 36 %. This is in the range shown by two crystallized proteins. One of them (2BYS) is the wild type AChBP, the other is the incomplete conversion of AChBP into the extracellular domain (ECD) of the alpha7 nAChR (5AFH), in which the extracellular interface was converted (chimerized). These two proteins can be regarded as "synthetic subtypes". In these two structures we find very high structural similarity in loops A, G, and D, small differences in loop E, large differences -as expected on the basis of sequence differences -in loops C and F, see . Fig. 2b . Furthermore, surprisingly large differences are observed around loop B which would not have been expected on the basis of the rather similar sequences. Differences between the GAB-A A receptor beta3 structure and other subunit classes, such as gamma or alpha subunits, will be in the same ballpark range as those shown in . Fig. 2b . Thus, homology models of alpha or gamma subunits will be fairly accurate in the extracellular loops A, G, D and E, but less so in the interesting variable regions C and F, and will also be uncertain in the loop B region. Furthermore, the bound conformation of larger ligands than the benzamidine present in the beta3 crystal structure can also not be predicted reliably. To be able to estimate the range of inaccuracy of a model on the basis of structure comparisons like this one is very helpful for the interpretation of the models.
Binding sites at the trans-membrane interface. This binding site is very similar in three different receptors, see . Fig. 2a and c, which argues for a high degree of structural conservation in this region/microdomain. The specificity of ligands that bind here often rests on a single sidechain, as is the case for an asparagine/serine polymorphism in the TM2 of the GABA A receptor beta subunits [1] , which makes the beta1 subunit insensitive to etomidate. This binding site is thus not affected by (backbone) structural variability, not even in situations of low sequence similarity, owing to the high structural conservation of the four helix motif -but it is all the more "in motion". The TM domains terface-forming segments A to G of the principal-and complementary subunits, the positions of the disulfide-forming cysteines (yellow bars), the four transmembrane domaines (TM1-4) with the position of their interface-forming plus and minus segments, and the intracellular domaine (ICD). b Pentameric structure of the most abundant GABA A receptor subtype consisting of two alpha1, two beta2, and one gamma2 subunit, view from extracellular, and based on a homology model using the crystal structure of Miller and Aricescu as a template. This structure has no intracellular domain. The five "backbone"-helices shown are the five TM2 helices that form the chloride channel. In addition, the location of the GABA, benzodiazepine (BZ) and alpha + beta − binding sites of the extracellular interfaces is indicated by arrows. The + and − side of the subunits is indicated at the outside circumference. c Side view of a homology model based on the crystal structure of Miller and Aricescu where the intracellular domain is based on the crystal structure of the 5-HT 3 receptor. Shown is a principal and a complementary subunit with the extracellular loops in pink, orange, red, green, and cyan, and the plus (blue) and minus (purple) side of the transmembrane-interfaces, as well as the intracellular domains in the same color code as in a of the GABA A receptor, the 5-HT 3 receptor (14 % sequence identity with the GA-BA A R) and one of the GluCl structures are very similar and the protein backbone overlays very well, see . Fig. 2 . All three proteins are in a similar conformation and the region around the TM-interface binding site is structurally very conserved. In contrast, the TM domains of different GluCl structures (3RIF from [14] on the one hand, and 4TNV as well as 4TNW from [11] on the other hand) are very different, see . Fig. 2 . This is due to the large conformational flexibility of this region.
In this respect it must be noted that structures in crystals not necessarily look like structures in the cell, because they are not only determined by the presence or absence of ligands, but also by stabilizing antibodies, lipids, detergents, the crystallization cocktails and the orientation and contacts of the receptors within the crystal. However, as the GluCl features widely different conformations under different conditions, we must assume that the mobility of this region is comparable also in GABA A receptors and that the size and shape of the binding pockets undergo comparable motion as in the GluCl. This is well compatible with the observation that ligands of the TM interface binding sites often show strong use-dependent potency differences [16] , that can be caused by allosteric interactions with other binding sites. For computational methods such as in silico docking ideally the structure with the correct state should be chosen as modeling template -and that is not necessarily the GABA A receptor itself. Since it is often not clear which functional state a crystal structure best matches, it is recommend to compare several crystal structures and not to overinterpret models based on a single template structure.
The present analysis of the homopentameric beta3 GABA A receptors in comparison with structures of homologues demonstrate the impressively conserved scaffold, but also the subtle structural variability of the extracellular domain and the very high mobility of the upper part of the transmembrane domain. The crystal structures that are now available still preclude specific conclusions on structural differences between GABA A receptor subtypes, but they provide excellent guidance in estimating local uncertainties of homology models. Particularly noteworthy is the structural variability of the loop B region (See . Fig. 2b ) despite the high sequence conservation of this region.
In conclusion, it can be stated that the progress in understanding the complexity of the GABA A receptor family is accelerated tremendously by the synergy between structural biology, biochemistry, and pharmacology. The identification of novel and interesting receptor subtypes in neuronal and non neuronal tissues and the study of their function makes them clinically interesting target molecules. The determination of their subunit arrangements and of their structure at the atomic level should enable structure-guided drug development and soon lead to the identification of specific ligands. These not only Excursion 2 From the discovery of the neurotransmitter GABA to the heterogeneity of GABA A receptors
In 1950, the amino acid GABA was first identified in the brain, after it had been known to exist in bacteria, yeasts, and plants. In 1958, it became clear that the conductance increase in crustacean muscle fibers caused by inhibitory nerve stimulation resulted from an increased permeability towards chloride ions and that externally applied GABA exactly duplicated the action of inhibitory nerve stimulation. During the following years a possible role of GABA as a transmitter compound was heavily disputed with many pro's and con's. The identification of bicuculline as an antagonist of GABA action in 1970 then provided a new powerful tool to study the distribution of GABAergic synapses in the CNS. Subsequently, it became clear that most but not all of the GABA actions could be blocked by bicuculline (the respective receptors were defined as GABA A receptors), whereas other GABA actions could be blocked by baclofen (GABA B receptors). Whereas GABA A receptors are GABA-activated anion channels, GABA B receptors are G-protein coupled receptors with a different structure, function and pharmacology. Benzodiazepines, such as chlordiazepoxide (Librium) [17] for the first time provided evidence for a molecular heterogeneity of GABA A receptors. Although this evidence was then further supported by a variety of biochemical and pharmacological studies from the same as well as from other laboratories, a heterogeneity of GABA A receptors was finally believed only after 1987, when the cloning of various GABA A receptor subunits had been reported by the group of Peter Seeburg and others. Today it is clear that a total of 19 distinct GABA A receptor subunits (alpha1-6, beta1-3, gamma1-3, epsilon, delta, pi, theta and rho1-3) as well as several alternatively spliced isoforms of some of these subunits are expressed in mammalian nervous system as well as in peripheral mammalian tissues. Since GABA A receptors are composed of five subunits that form the central anion channel, many thousands of different GABA A receptor subtypes could theoretically be formed from random combinations of the 19 subunits. The overall number of distinct receptor subtypes is limited, however, by the rules of assembly, leading to defined subunit stoichiometries, as well as by preferential subunit partnerships and excluded subunit combinations. Thus, the majority of GABA A receptors is composed of two alpha, two beta, and one gamma subunit. In these receptors a total of four alternating alpha and beta subunits are connected by a gamma subunit (. Fig. 1) . Whether all receptors composed of alpha, beta, and gamma subunits or also those composed of alpha, beta, and delta subunits exhibit the same subunit stoichiometry and subunit arrangement presently is not known or controversial. The subunit combinations containing epsilon, theta, or pi subunits are at present unclear. The rho subunits form homo-oligomeric or hetero-oligomeric receptors with other rho subunits, and may co-assemble with additional subunits as well. GABA A receptor subtypes might contain up to five different subunits, but gamma subunits seem not to co-assemble with other gamma-or delta-subunits. Nevertheless, even then it was estimated that a maximum of the order of 800 subunit combinations of the types observed so far might exist [18] . The true number is likely to be far smaller. Recently, the evidence accumulated for the existence of 11 native receptor subtypes was considered strong enough for the assumption that they really exist in vivo. An additional 15 receptor subtypes seem to exist with high probability [18] , but the number for sure will increase. The actual heterogeneity of GABAA receptors is thus much larger than previously assumed.
can then be developed to novel therapeutic principles for the treatment of neuropsychiatric disorders, but also for disorders of other organs in which GABA acts as signaling molecule. . Fig. 1 . c Binding site at the trans-membrane (TM)-interface of the glutamate-activated chloride channel (GluCl) (3RIF, bluegreen) in comparison with the homo-oligomeric beta3 GABA A receptor (blue and red), shown as top view and side view. In the area of the TM-interface binding site an alpha carbon atom is shown in a space filling mode at a homologous position of the TM2 and TM3 of the one as well as at the TM2 and TM1 helix of the other subunit to allow orientation at the interface. In the perspective view from above it can be seen that the atoms are located at both sides of the interface, and are located quite similarly in the two structures. In the perspective side view the TM2 of the minus side is located exactly behind the TM1 and is thus, partially obscured. d Comparison of the same binding site at the apo-GluCl receptor (4TNV, green) and the GABA A receptor (blue and red)from identical perspectives as in c. In the top view of d, the green atom in TM1, that is seen exactly from above in a view parallel to the TM1 helix, is obscured by the red atom and is marked by a green circle. It clearly can be seen that the TM helices fit quite well to each other in c, but have clearly different conformations in d. Similarly, the labeled amino acid atoms differ much more in d than in c established molecular genetic investigations in the blood of patients for linkage and association studies. 
